Merck & Co
Merck & Co., Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$65.0B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
38.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★★★★☆position among all companies
7.5%
Capital efficiency
★★★★★position among all companies
34.7%
Revenue and profit
Performance, financial position and capital allocation
Merck & Co
Recent performance trends
Merck & Co
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$48.7 billion | US$59.3 billion | US$60.1 billion | US$64.2 billion | US$65.0 billion |
| Net income | US$13.0 billion | US$14.5 billion | US$0.4 billion | US$17.1 billion | US$18.3 billion |
| Total assets | US$105.7 billion | US$109.2 billion | US$106.7 billion | US$117.1 billion | US$136.9 billion |
| Shareholders' equity | US$38.2 billion | US$46.0 billion | US$37.6 billion | US$46.3 billion | US$52.6 billion |
| Net cash provided by (used in) operating activities | Could not be retrieved | US$19.1 billion | US$13.0 billion | US$21.5 billion | US$16.5 billion |
| Net cash provided by (used in) investing activities | Could not be retrieved | US$-5.0 billion | US$-14.1 billion | US$-7.7 billion | US$-13.7 billion |
| Net cash provided by (used in) financing activities | Could not be retrieved | US$-9.1 billion | US$-4.8 billion | US$-7.0 billion | US$-1.9 billion |
| Cash and cash equivalents | US$8.1 billion | US$12.7 billion | US$6.8 billion | US$13.2 billion | US$14.6 billion |
Revenue scale in the same industry
Merck & Co
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- 4 Merck & CoThis companyFY Dec 2025 US$65.0B
- 5 PfizerFY Dec 2025 US$62.6B
- 6 AbbVieFY Dec 2025 US$61.2B
- … 50 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$4.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$14.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-13.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$16.5 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$3.0 billion | Consolidated | Disclosed |
| Dividends paid | US$8.2 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$52.7 billion | Consolidated | Disclosed |
| Non-controlling interests | US$56.00 million | Consolidated | Disclosed |
| Net assets | US$52.6 billion | Consolidated | Disclosed |
| Net sales | US$65.0 billion | Consolidated | Disclosed |
| Net income | US$18.3 billion | Consolidated | Disclosed |
| Total assets | US$136.9 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$5.1 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 38.4% | Consolidated | Calculated |
| Net margin | 28.1% | Consolidated | Calculated |
| Return on equity | 34.7% | Consolidated | Calculated |